Medical Department, Division of Hepatology and Gastroenterology, Chariteġ0117, Berlin, Germany. Support PN, Parenteral nutrition IVF, Intravenous fluid (fluid and electrolytes alone) BIA, Bioelectrical impedance analysis BW, Body weight IFALD, Intestinal failureĪssociated liver disease CRBSI, Catheter-related bloodstream infections QoL, Quality of life BMI, Body mass index. Teduglutideinduced functional and structural changes bring on a gradual reduction of parenteral support at no costĪbbreviations: GLP-2, Glucagon-like peptide-2 SBS, Short bowel syndrome IF, Intestinal failure SBS-IF, Short bowel syndrome associated intestinal failure PS, Parenteral Results in an adaptive response with variable time and effect range in routine medical care. Intestinal mucosa with significantly increased villus height, crypt depth and plasma citrulline levels.Ĭonclusions: Teduglutide can be applied to anatomically and clinically heterogeneous SBS-IF patients and Structural effects of teduglutide treatment were observed on small Subgroup analysis revealed long-term stability in body weight, albumin levels and body compositionĪlbeit parenteral support reduction. Teduglutide-mediated improvement of stool frequency and consistency. We also report on a clinically relevant and significant effect of Treated for 3 months to about 45% in patients treated for 2 years. Significant parenteral support reductions were observed, ranging from about 20% in patients A clinically significant reduction of parenteral volume was observed in 15/19 patients (79%) with onset between 1 and 45 Parenteral nutrition independency wasĪchieved in 4/19 (21%) patients analyzed, with two remaining on intravenous fluids. Results: In total, 27 patients were treated with teduglutide. Retrospectively from a single university medical center. Within a structured multidisciplinary program to enhance intestinal rehabilitation, were analyzed Methods: Data of adult SBS-IF patients, treated with teduglutide between Sept. Teduglutide's effects in routine medical care with focus on clinical and nutritional effects. The present report aims to describe the experience of The need for parenteral support in clinical trials. Due to its intestinotrophic properties, it improves intestinal absorption of fluids an d nutrients, which was shown to reduce Specific for short bowel syndrome patients with chronic intestinal failure (SBS-IF). Medical Department, Division of Gastroenterology, Oncology, Hematology, Rheumatology and Diabetes, Ruppiner Kliniken, Brandenburg Medical School,īackground
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |